M

MacroGenics
D

MGNX

1.44000
USD
-0.01
(-0.69%)
مفتوح الان
حجم التداول
900
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
90,850,065
أصول ذات صلة
ABBV
ABBV
1.800
(0.95%)
191.280 USD
AZN
AZN
0.330
(0.47%)
69.950 USD
BMY
BMY
-0.430
(-0.91%)
46.650 USD
GILD
GILD
1.390
(1.26%)
112.150 USD
INCY
INCY
-0.760
(-1.11%)
67.710 USD
MRK
MRK
0.395
(0.49%)
81.350 USD
N
NKTR
-1.485
(-5.99%)
23.290 USD
PFE
PFE
0.080
(0.31%)
25.470 USD
المزيد
الأخبار المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.